Skip to content
Checking whether you are signed in

AbbVie Inc.

ABBVNew York Stock ExchangeFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 3, 2026, 1:57 PM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

AbbVie sells prescription medicines, mostly in the United States, and two immunology drugs, Skyrizi and Rinvoq, now bring in nearly half of its revenue and almost all of its growth. In the third quarter of 2026 revenue grew 10.3% to $17.404 billion and adjusted earnings again came in above the company's own range, but adjusted figures leave out the royalties AbbVie pays on Skyrizi and much of what it spends buying new drugs. The key question is what AbbVie earns after Skyrizi and Rinvoq lose exclusivity between 2031 and 2037, which depends on medicines it is still developing or buying. Moatsight estimates revenue of about $71.1 billion and GAAP diluted EPS of about $6.60 over the next four quarters.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers